Paper36979809
A Brief Review of Duchenne Muscular Dystrophy Treatment Options, with an Emphasis on Two Novel Strategies.
Heydemann A and 1 other. Biomedicines, 2023. Cited by 22 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. A Brief Review of Duchenne Muscular Dystrophy Treatment Options, with an Emphasis on Two Novel Strategies. Papers, record 36979809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36979809
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A Brief Review of Duchenne Muscular Dystrophy Treatment Options, with an Emphasis on Two Novel Strategies.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References100
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32,946,430 | Stem cell therapy for muscular dystrophies. | J Clin Invest | 2020 | https://conductscience.org/library/papers/32946430 | PubMed |
| 2 | 28,391,962 | SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy. | Mol Ther | 2017 | https://conductscience.org/library/papers/28391962 | PubMed |
| 3 | 18,444,914 | Hematopoietic stem cell engraftment and seeding permits multi-lymphoid chimerism in vascularized bone marrow transplants. | Am J Transplant | 2008 | https://conductscience.org/library/papers/18444914 | PubMed |
| 4 | 22,068,425 | Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. | Mol Ther | 2012 | https://conductscience.org/library/papers/22068425 | PubMed |
| 5 | 1,483,043 | The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibres in dystrophies and inflammatory myopathies. | Neuromuscul Disord | 1992 | https://conductscience.org/library/papers/1483043 | PubMed |
| 6 | 15,806,097 | Highly efficient endogenous human gene correction using designed zinc-finger nucleases. | Nature | 2005 | https://conductscience.org/library/papers/15806097 | PubMed |
| 7 | 19,933,107 | Breaking the code of DNA binding specificity of TAL-type III effectors. | Science | 2009 | https://conductscience.org/library/papers/19933107 | PubMed |
| 8 | 33,669,654 | Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/33669654 | PubMed |
| 9 | 26,417,069 | A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy. | Proc Natl Acad Sci U S A | 2015 | https://conductscience.org/library/papers/26417069 | PubMed |
| 10 | 31,039,133 | Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy. | JCI Insight | 2019 | https://conductscience.org/library/papers/31039133 | PubMed |
| 11 | 35,634,851 | Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy. | J Neuromuscul Dis | 2022 | https://conductscience.org/library/papers/35634851 | PubMed |
| 12 | 31,664,444 | Effect of Combination l-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. | JAMA Netw Open | 2019 | https://conductscience.org/library/papers/31664444 | PubMed |
| 13 | 29,705,868 | New Hope for Treatment of Duchene Dystrophy by Employing Dystrophin Expressing Chimeric Cells - Studies Published in Stem Cell Reviews and Reports. | Stem Cell Rev Rep | 2018 | https://conductscience.org/library/papers/29705868 | PubMed |
| 14 | 35,221,289 | Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. | Drug Metab Dispos | 2022 | https://conductscience.org/library/papers/35221289 | PubMed |
| 15 | 31,789,220 | Muscular dystrophies. | Lancet | 2019 | https://conductscience.org/library/papers/31789220 | PubMed |
| 16 | 29,203,355 | A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. | Neuromuscul Disord | 2018 | https://conductscience.org/library/papers/29203355 | PubMed |
| 17 | 34,592,975 | Long term treatment with ataluren-the Swedish experience. | BMC Musculoskelet Disord | 2021 | https://conductscience.org/library/papers/34592975 | PubMed |
| 18 | 23,473,647 | Duchenne muscular dystrophy drug discovery - the application of utrophin promoter activation screening. | Expert Opin Drug Discov | 2013 | https://conductscience.org/library/papers/23473647 | PubMed |
| 19 | 18,006,908 | Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point. | Cancer Epidemiol Biomarkers Prev | 2007 | https://conductscience.org/library/papers/18006908 | PubMed |
| 20 | 32,539,076 | Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. | JAMA Neurol | 2020 | https://conductscience.org/library/papers/32539076 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,703,430 | A Registry-Based Perspective of Interventional Clinical Trials for Duchenne Muscular Dystrophy. | Cureus | 2026 | https://conductscience.org/library/papers/42703430 | PubMed |
| 42,251,435 | Bacteroides-derived endocannabinoid-like commendamide attenuates skeletal muscle ferroptosis in vitro: implications for Duchenne muscular dystrophy. | J Transl Med | 2026 | https://conductscience.org/library/papers/42251435 | PubMed |
| 42,096,741 | Generation of an induced pluripotent stem cell line (NCHi026-A) from a patient with a partial deletion of exon 55 in the DMD gene. | Stem Cell Res | 2026 | https://conductscience.org/library/papers/42096741 | PubMed |
| 41,961,170 | Estimating health-state utility values for family-caregivers of patients with Duchenne muscular dystrophy using time trade-off valuation. | J Patient Rep Outcomes | 2026 | https://conductscience.org/library/papers/41961170 | PubMed |
| 41,466,293 | Assessing rare disease understanding: a novel disease readiness level framework. | Orphanet J Rare Dis | 2025 | https://conductscience.org/library/papers/41466293 | PubMed |
| 41,410,800 | Long-Term Safety and Efficacy of Systemic DT-DEC01 Cell Therapy in Non-Ambulatory Duchenne Muscular Dystrophy Patients: a 24-Month Clinical Evaluation. | Stem Cell Rev Rep | 2026 | https://conductscience.org/library/papers/41410800 | PubMed |
| 41,307,959 | Proteomics-based evaluation of AAV dystrophin gene therapy outcomes in mdx skeletal muscle. | JCI Insight | 2026 | https://conductscience.org/library/papers/41307959 | PubMed |
| 40,869,293 | Integrative Approaches to Myopathies and Muscular Dystrophies: Molecular Mechanisms, Diagnostics, and Future Therapies. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40869293 | PubMed |
| 40,195,304 | The SIRT1 activator SRT2104 exerts exercise mimetic effects and promotes Duchenne muscular dystrophy recovery. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/40195304 | PubMed |
| 40,150,443 | The Uneven Effect of Rare Diseases on Functional Status and Work Capacity. | Healthcare (Basel) | 2025 | https://conductscience.org/library/papers/40150443 | PubMed |
| 39,778,566 | Safety and Tolerability of Wharton's Jelly-Derived Mesenchymal Stem Cells for Patients With Duchenne Muscular Dystrophy: A Phase 1 Clinical Study. | J Clin Neurol | 2025 | https://conductscience.org/library/papers/39778566 | PubMed |
| 39,337,654 | The Effects of Growth Hormone Treatment Beyond Growth Promotion in Patients with Genetic Syndromes: A Systematic Review of the Literature. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39337654 | PubMed |
| 39,017,908 | Chimeric Cell Therapy Transfers Healthy Donor Mitochondria in Duchenne Muscular Dystrophy. | Stem Cell Rev Rep | 2024 | https://conductscience.org/library/papers/39017908 | PubMed |
| 38,501,170 | Cross-species modeling of muscular dystrophy in Caenorhabditis elegans using patient-derived extracellular vesicles. | Dis Model Mech | 2024 | https://conductscience.org/library/papers/38501170 | PubMed |
| 37,999,748 | Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration. | Arch Immunol Ther Exp (Warsz) | 2023 | https://conductscience.org/library/papers/37999748 | PubMed |
| 37,991,502 | mCherry on Top: A Positive Read-Out Cellular Platform for Screening DMD Exon Skipping Xenopeptide-PMO Conjugates. | Bioconjug Chem | 2023 | https://conductscience.org/library/papers/37991502 | PubMed |
| 37,707,670 | Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration. | Stem Cell Rev Rep | 2023 | https://conductscience.org/library/papers/37707670 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| DMD | 1,756 | PubTator's text mining | https://conductscience.org/library/genes/1756 | NCBI Gene |
| ESR1 | 2,099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| ITGA7 | 3,679 | PubTator's text mining | https://conductscience.org/library/genes/3679 | NCBI Gene |
| PPARGC1A | 10,891 | PubTator's text mining | https://conductscience.org/library/genes/10891 | NCBI Gene |
| UTRN | 7,402 | PubTator's text mining | https://conductscience.org/library/genes/7402 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36979809
GET https://conductscience.org/api/papers/v1/36979809/references?page=2